News

Companies in The News Are: ACN,NVO,NVDA,AVGO

Roche (USOTC:RHHBY) has reported positive results from a mid-stage clinical trial of its experimental obesity treatment enicepatide, with patients who have type 2 diabetes achieving average weight loss of 15. 5% alongside improvements in blood sugar control.

Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.

Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.

Find insight on Novo Nordisk, Roche Holding, IHH Healthcare and more in the latest Market Talks covering Health Care.

Semaglutide will start losing patent protection in the near future.

Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the selloff created the most compelling entry point in the GLP-1 giant's recent history.

Novo Nordisk (NYSE:NVO) pulled back the curtain on its future at an investor day in London, and the audience filed out distinctly underwhelmed. The Danish drugs giant, best known for the weight-loss sensation Wegovy, used its biennial capital markets day to explain how it will thrive once its...

Novo Nordisk (NYSE:NVO) is considering acquisitions to strengthen its weight-loss drug pipeline and expand into related therapeutic areas as competition increases, Chief Executive Mike Doustdar said on Tuesday. Speaking to CNBC’s Squawk Box Europe, Doustdar said the Danish pharmaceutical company was examining opportunities to address gaps in its portfolio, including acquiring medicines that could complement or outperform treatments developed internally.

Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.

Novo Nordisk A/S (NYSE:NVO) has partnered with Anthropic to use Claude models and Claude Science in its research and development workflows, with the initial focus on specific scientific problems where AI can have the greatest impact. Novo will also use Anthropic’s frontier models for AI-driven software development. Reuters reported that Novo already uses Claude to […]

Novo Nordisk (CPSE:NOVO B) outlined a new 2030 plan targeting several potential blockbuster therapies beyond obesity and diabetes. Management used its recent Capital Markets Day to highlight a broader pipeline focus and an expanded manufacturing footprint for future launches. Investors reacted coolly to the update, citing limited near term guidance and rising competitive pressure as key concerns. The reaction to Novo Nordisk's long term 2030 blockbuster plan is worth weighing against the...

(Updates with market moves at the end of the day, and other changes, if any.) The Nasdaq Composit

Chair and CEO Dave Ricks told CNBC that about one-third of new patients starting a GLP-1 tablet are now on Foundayo, and that Lilly’s share of that oral market is still rising week by week.

Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index increasing 0.6% and the

CagriSema beat 5-milligram tirzepatide in diabetes--not Lilly's full dosing range or broader obesity franchise.

Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular conditions, and a growing focus on consumer-facing prescription medicine channels. The company said it

(Updates with latest market prices and developments.) US benchmark equity indexes were higher int

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index increasing 0.5% and the Stat

No one expects a lot of growth from Novo Nordisk anymore -- not even Novo Nordisk itself.

European stock markets closed higher Monday as oil prices tumbled and investors looked ahead to US P

Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...

Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth

All three major US stock indexes were up in late-morning trading Monday, as oil prices and Treasury

The Danish drugmaker fell as much as 9% after its Capital Markets Day promised new blockbusters and broader growth but failed to give investors the certainty they wanted beyond Wegovy and Ozempic.

European equities traded in the US as American depositary receipts started the week higher on Monday

Novo Nordisk has come under pressure after a prolonged slide in the share price, and the key issue now is whether the current valuation still lines up with what its earnings can reasonably support. With the stock well off its highs despite regular headlines about obesity drugs, AI partnerships and new therapies, investors are asking if the earnings story and the price tag still match. Over the past 3 years the share price has fallen 51.9%, which puts the spotlight squarely on whether the...

NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Yahoo Finance Executive Editor Brian Sozzi outlines a few unexpected events driving markets this week. For a closer look, watch the video above.